SLC5A2 and Schnyder corneal dystrophy: They concluded that there was no significant association between therapy with SGLT2 inhibitors and SCD (risk ratio: 0.74; 95% confidence interval: 0.50–1.08) and that treatment with SGLT inhibitors was not associated with a lower risk of VAs (risk ratio: 0.84; 95% confidence interval: 0.66–1.06).